Artikel & Studien
Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.
E. Walter, F. Torelli, T. Barbui
Annals of Hematology. Jan 2025
siehe Link
Cost-effectiveness of the Floodlight® MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis.
E. Walter, M. Traunfellner, F. Meyer, C. Enzinger, M. Guger, C. Bsteh, P. Altmann, H. Hegen, C. Goger, V. Mikl
Digital Health. Jan 2025
siehe Link
Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective.
E. Walter, C. Dawoud, E. Hütterer, A. Stift, F. Harpain
The American journal of clinical nutrition. 2024
siehe Link
A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: an original research.
G. Eichhober, M. Voit, F. Meyer, E. Walter
Health Sci Rep. 2024
siehe Link
The cost-of-illness and burden-of-disease of treatment-resistant depression in Austria.
E. Walter, M. Traunfellner, M. Gleitsmann, M. Zalesak, C. Helmenstein
J Med Econ. 2023
siehe Link
Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type 2 diabetes in Austria and Switzerland.
E. Walter, M. Arrigo, S. Allerstorfer, P. Marty, M. Hülsmann
J Med Econ. 2023
siehe Link
Exploring the Economic and Social Dimension of COVID-19 Vaccination Using a Budget Impact Analysis.
M. Traunfellner, F. Meyer, E. Walter
Value & Outcomes Spotlight. 2022
siehe Link (Seite 18-21)
Impact of metabolic surgery on long-term health outcome: a cost-effectiveness approach.
E. Walter, F. B. Langer, P. Beckerhinn, F. Hoffer, G. Prager
Surg Obes Relat Dis. 2022
siehe Link
Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
E. Walter, M. Voit, G. Eichhober
Expert Rev Pharmacoecon Outcomes Res. 2021
siehe Link
Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria.
E. Walter, S.C. Hausberger, E. Groß, U. Siebert
J Med Econ. 2020
siehe Link
Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.
E. Walter, G. Eichhober, M. Voit, C. Baumgartner, A. Celedin, C. Holzhauser, B. Mraz, C. Ornauer, J. Pleiner-Duxneuner, B. Ponner, I. Presch, G. Pum, H. Tieben, G. Weingartmann, D. Baltic, W. Bonitz, S.T. Kaehler.
J Med Econ. 2020
siehe Link
Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System.
E. Walter, M. Heringlake
J Cardiothorac Vasc Anesth. 2019 Nov 9.
siehe Link
Approaches to Capturing Value in Oncology.
E. Walter
In: E. Walter (eds) Regulatory and Economic Aspects in Oncology. Recent Results in Cancer Research, vol 213. Springer, Cham
siehe Link
Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
E. Walter, T. Berger, B. Bajer-Kornek, F. Deisenhammer
J Med Econ. 2019 Mar; 22(3): 226-237.
siehe Link
Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population.
E. Walter, H. Dellago, J. Grillari, H. P. Dimai
Hackl M. Bone. Mar 2018; 108:44-54
siehe Link
Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving.
A. R. Prusa, D.C. Kasper, L. Sawers, E. Walter, M. Hayde, E. Stillwagon
PLoS Negl Trop Dis., Jul 2017
siehe Link
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany
E. Walter, P. Odin
J Med Econ. 2015 Feb; 18(2):155-65.
siehe Link
Socio-economic aspects of the testing for antibodies in MS-Patients under Interferon Therapy in Austria: A cost of Illness Study
E. Walter, F. Deisenhammer
Multiple Sclerosis and Related Disorders. 2014, Volume 3, Issue 6, Pages 670-677.
siehe Link
Kosteneffektivität der primärprofilatischen Gabe von Pegfilgrastim vs. Filgrastim bei Brustkrebspatienten in Österreich
E. Walter
Recht der Medizin Beilage Gesundheit und Ökonomie, Dezember 2013
Cost Efectividad del Tratamiento de la Anemia inducida por quimioteerapia con agentes estimuladores dela Eritropoyesis
C. A. Rodríguez, A. Alegre, J. Cassinello, L. Guiérrez, C. Crespo, A. Villacampa, E. Walter
PharmaEconomics Spanish Resarch Articles, August 2013
siehe Link